Document Detail


Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting.
MedLine Citation:
PMID:  19161801     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor antagonists prevent platelet aggregation and thrombus formation, improving outcomes of patients with acute coronary syndrome. Therapy with these agents may lead to bleeding complications and thrombocytopenia, challenging the perioperative management of patients undergoing coronary surgery. We report the successful management of an acute profound thrombocytopenia after urgent off-pump coronary surgery in a patient treated with tirofiban for unstable angina and acute coronary syndrome.
Authors:
Andres Beiras-Fernandez; Anke Kowert; Pascale Jiru; Marion Weis; Michael Spannagl; Bruno Reichart; Michael Schmoeckel
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The Annals of thoracic surgery     Volume:  87     ISSN:  1552-6259     ISO Abbreviation:  Ann. Thorac. Surg.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-23     Completed Date:  2009-02-11     Revised Date:  2009-08-24    
Medline Journal Info:
Nlm Unique ID:  15030100R     Medline TA:  Ann Thorac Surg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  629-31     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiac Surgery, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany. andres.beiras@med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / diagnosis,  drug therapy,  surgery
Acute Disease
Angina, Unstable / diagnosis,  drug therapy,  surgery
Coronary Angiography
Coronary Artery Bypass, Off-Pump / adverse effects,  methods*
Follow-Up Studies
Heparin / adverse effects,  therapeutic use
Humans
Infusions, Intravenous
Male
Middle Aged
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use
Platelet Count
Platelet Transfusion / methods*
Postoperative Complications / prevention & control
Preoperative Care / methods
Risk Assessment
Severity of Illness Index
Thrombocytopenia / chemically induced*,  diagnosis,  therapy*
Thrombosis / prevention & control*
Treatment Outcome
Tyrosine / adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 144494-65-5/tirofiban; 55520-40-6/Tyrosine; 9005-49-6/Heparin
Comments/Corrections
Comment In:
Ann Thorac Surg. 2009 Sep;88(3):1048; author reply 1048   [PMID:  19699965 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A 37-year-old Smeloff-Cutter aortic valve.
Next Document:  Recurrent ventricular arrhythmia after coronary artery bypass grafting treated with radiofrequency c...